source
- AstraZeneca and Amgen report positive Phase 3 results for Tezspire in eosinophilic esophagitisAstraZeneca and Amgen announced that their joint drug Tezspire met primary and secondary endpoints in a late-stage Phase 3 trial for eosinophilic esophagitis. The antibody targets TSLP and had pre…
- Scaling delivery is key for CAR T therapies to succeed in autoimmune diseasesBiopharma companies are exploring CAR T cell therapies as a potential cure for autoimmune disorders, a market that could be twice the size of oncology. While current treatments manage symptoms, the…